Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,190.00-1.30%ETH$2,459.99-0.30%GOLD$4,358.50-2.29%OIL$103.93+8.20%
Smart Investors Daily
PS

NASDAQ · PSTV

Plus Therapeutics, Inc.

Healthcare · Biotechnology

$3.87

Down-$0.13 (-3.25%)

Updated Sep 10, 2026, 8:48 PM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
43.52M
P/E ratio
-3.76
Dividend yield
0.00%
52-week range
$0.23 – $8.00
Volume
96.53K
Avg. volume
18.87M

Price performance

PSTV price history

1M range · 0 trading sessions · Daily adjusted prices

PSTV does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest PSTV news

The latest Smart Investors Daily articles mentioning PSTV.

Stock researchCompany · Overview

PSTV research

Overview

Company profile and research snapshot.

Company profile

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$2.00
Implied upside
—
Analysts
—
PSTV recent ratings
DateFirmRatingTarget
Jun 8, 2026Ascendiant CapitalBuy—
Apr 9, 2026Ascendiant CapitalBuy—
Mar 31, 2026D. Boral CapitalHold—
Mar 19, 2026D. Boral CapitalBuy—
Jan 23, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jul 21, 2026

Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

HOUSTON, July 21, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout Ohio and Kentucky, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to approximately 127

Yahoo · Jul 16, 2026

Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform

Collaboration expected to deliver hundreds of DNA and RNA biomarkers from a single CSF specimen — directly aligned with the updated NCCN Guidelines® (Version 2.2026), which now recognize CSF circulating tumor cells alongside tumor-derived DNA and broaden the leptomeningeal treatment algorithm from “CSF cytology” to “CSF analysis”HOUSTON and LAKE FOREST, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”) and Genomic Testing Cooperative, LCA

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By